Whether administering such drugs prophylactically

for post-resuscitation care after ROSC prevents re-arrest and improves outcome is unstudied.

Methods: We evaluated a cohort of 1721 patients with witnessed VF/VT OHCA who did (1296) or did not receive prophylactic lidocaine (425) at first ROSC. Study endpoints included re-arrest, hospital admission and survival.

Results: Prophylacic lidocaine recipients and non-recipients were comparable, except for shorter time to first ROSC and higher systolic blood pressure at ROSC in those receiving lidocaine. After initial ROSC, arrest from VF/VT recurred in 16.7% and from non-shockable arrhythmias in 3.2% of prophylactic lidocaine recipients, 93.5% of OICR-9429 research buy whom were admitted to hospital and 62.4%

discharged alive, as compared with 37.4%, 7.8%, 84.9% and 44.5%, of corresponding non-recipients (all p < 0.0001). Adjusted for pertinent covariates, prophylactic lidocaine was independently associated with reduced odds of re-arrest from VF/VT, odds ratio, (95% confidence interval) 0.34 (0.26-0.44) and from nonshockable arrhythmias (0.47 (0.29-0.78)); a higher hospital admission rate (1.88, (1.28-2.76)) and improved AZ 628 research buy survival to discharge (1.49 (1.15-1.95)). However in a propensity score-matched sensitivity analysis, lidocaine’s only beneficial association with outcome was in a lower incidence of recurrent VF/VT arrest.

Conclusions: Administration of prophylactic lidocaine upon ROSC after OHCA was consistently associated with less recurrent VF/VT arrest,

and therapeutic equipoise for other measures. The prospect of a promising association between find more lidocaine prophylaxis and outcome, without evidence of harm, warrants further investigation. (C) 2013 Elsevier Ireland Ltd. All rights reserved.”
“The review considers transformations of ecdysteroids (mostly of 20-hydroxyecdysone and its derivatives) involving the A, B, C, and D rings of the steroid skeleton and the side chain, which are used in the synthesis of minor phyto- and zooecdysteroids and structural analogs of ecdysteroids.”
“Background: Compliant vascular phantoms are desirable for in-vitro patient-specific experiments and device testing. TangoPlus FullCure 930 (R) is a commercially available rubber-like material that can be used for PolyJet rapid prototyping. This work aims to gather preliminary data on the distensibility of this material, in order to assess the feasibility of its use in the context of experimental cardiovascular modelling.

Methods: The descending aorta anatomy of a volunteer was modelled in 3D from cardiovascular magnetic resonance (CMR) images and rapid prototyped using TangoPlus. The model was printed with a range of increasing wall thicknesses (0.6, 0.7, 0.8, 1.0 and 1.5 mm), keeping the lumen of the vessel constant.